Table 1 Baseline characteristics of subjects with schizophrenia at baseline and healthy control

From: Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study

Variables

Schizophrenia

Control

P value

 

n = 225

n = 175

 

Age (years); mean (SD)

37.31 (10.85)

39.44 (9.36)

0.040a

Gender (female); n (%)

135 (60.0)

121 (69.1)

0.061b

Smoker; n (%)

25 (11.3)

21 (12.0)

0.936b

Drinker; n (%)

10 (5.0)

30 (17.4)

<0.001b

Age of onset (years); mean (SD)

27.74 (9.70)

–

–

Duration of illness (years); mean (SD)

4.48 (2.67)

–

–

First-episode subjects; n (%)

40 (17.78)

–

–

BMI (kg/m2); mean (SD)

24.11 (3.85)

23.91 (3.14)

0.596a

FBG (mmol/L); mean (SD)

5.73 (1.78)

5.70 (1.02)

0.869a

TG (mmol/L); mean (SD)

1.25 (0.9)

1.17 (0.8)

0.354a

TC (mmol/L); mean (SD)

4.66 (1.12)

4.76 (0.97)

0.368a

VLDL (mmol/L); mean (SD)

0.58 (0.41)

0.54 (0.35)

0.308a

  1. BMI body mass index, FBG fasting blood glucose, TG triglyceride, TC total cholesterol, VLDL very low density lipoprotein, SD standard deviation
  2. aP values were calculated by two-tailed t-tests
  3. bP values were calculated by chi-square tests
Back to article page